Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B surface antigen vaccine + AS37A adjuvant system
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepatitis B surface antigen (HBsAg) vaccine + AS37A adjuvant system is an investigational recombinant protein subunit vaccine developed by GSK for the prevention of hepatitis B virus (HBV) infection. The vaccine consists of 20 μg of recombinant hepatitis B surface antigen formulated with 100 μg of GSK's proprietary Adjuvant System 37A (AS37A). AS37A is a novel adjuvant system composed of a Toll-like receptor 7 (TLR7) agonist adsorbed on aluminum hydroxide (alum). This combination is designed to enhance the immune response, potentially providing high concentrations of antigen-specific antibodies after a single injection and offering a more rapid or robust protective response compared to traditional alum-only vaccines. It is currently being evaluated in Phase I/IIa clinical trials (NCT05561673) to assess safety and immunogenicity in healthy, HBs-naïve adults.
- Other names
- AS37 adjuvanted hepatitis B vaccineAS-37 adjuvanted hepatitis B vaccineAS 37 adjuvanted hepatitis B vaccineHBsAg + AS37A
02
Targets
HBsAg (Hepatitis B surface antigen)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on hepatitis B surface antigen vaccine + AS37A adjuvant system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B surface antigen vaccine + AS37A adjuvant system.